On November 4, 2026 Ichnos Glenmark Innovation, Inc. (IGI), a global clinical-stage biotechnology company developing Multispecific therapeutics in oncology, reported that updated clinical data from the Phase 1 study of ISB 2001 (ABBV-2001) in relapsed/refractory multiple myeloma (RRMM) will be presented as an oral presentation at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"With longer follow-up from dose escalation and initial results from dose expansion, ISB 2001 (ABBV-2001) continues to demonstrate robust efficacy and tolerability in heavily pretreated patients with relapsed/refractory multiple myeloma," said Lida Pacaud, M.D., President and Chief Executive Officer of IGI. "These results represent an important milestone in the development of this first and only trispecific T-cell engager targeting CD38 x BCMA x CD3. Together with our partner, AbbVie, we remain focused on advancing ISB 2001 (ABBV-2001) as a potential new treatment option for patients with relapsed/refractory multiple myeloma (RRMM)."
ISB 2001 (ABBV-2001) Oral Presentation (abstract link):
First- and only-in-class CD38 x BCMA x CD3 trispecific T-cell engager ISB 2001 (ABBV-2001): Updated Phase 1 (TRIgnite-1) study data demonstrate robust efficacy and tolerability in relapsed/refractory multiple myeloma (RRMM)
Presenter: Binod Dhakal, M.D., Medical College of Wisconsin (MCW)
Date & Time: Saturday, December 12, 2026, 4–4:15pm CST
Room: La Nouvelle C at the Ernest N. Morial Convention Center, New Orleans
Session: 654. Multiple Myeloma: Pharmacologic Therapies: The March of Immunotherapy
About ISB 2001 (ABBV-2001)
ISB 2001 (ABBV-2001) is an investigational first- and only-in-class trispecific T-cell engager targeting CD38 and BCMA on myeloma cells and CD3 on T cells that is in development for the treatment of relapsed/refractory multiple myeloma (RRMM). Engineered using IGI`s BEAT Multispecific Platform, ISB 2001 (ABBV-2001) coordinates dual-antigen tumor recognition with immune engagement through T cells within a single molecular architecture. IGI and AbbVie formed an exclusive global licensing agreement for the trispecific in July 2025. ISB 2001 (ABBV-2001) is being evaluated in multiple myeloma through the Phase 1 TRIgnite-1 study and a Phase 1/2 combination study.
(Press release, Ichnos Sciences, NOV 4, 2026, View Source;utm_medium=rss&utm_campaign=ichnos-glenmark-innovation-igi-to-present-updated-clinical-data-for-isb-2001-abbv-2001-in-relapsed-refractory-multiple-myeloma-at-68th-ash-annual-meeting [SID1234674168])